Michael M. Millenson, MD

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Video: Michael Millenson, MD

Michael M Millenson, MD

Philadelphia Magazine
Top Doctors 2015

Patient Stories from Fox Chase Patients Dr. Millenson's
Patient Stories

Dr.  Michael M Millenson


Director, Hematology Service

Meet other members of the
lymphoma, leukemia and myeloma treatment team.
Meet other members of the 
lung cancer treatment team

Clinical Expertise:

LymphomaLeukemia; Thrombosis and Hemostasis, particularly the Hypercoagulable States; Development of New Preventive and Treatment Approaches for Venous Thrombosis


American Board of Internal Medicine, Internal Medicine, Hematology, Medical Oncology

Medical Education

Temple University School of Medicine, Phila., Pa., 1984


Internal Medicine, Temple University Hospital, Phila., Pa.


Hematology-Oncology, Harvard Medical School, Boston, Mass.; Hematology-Oncology, Beth Israel Hospital, Boston, Mass.

Honors and Awards

Best Doctors in America® 2013;
Philadelphia Magazine Top Doctors 2009-2015 

Research Interests

  1. Hematologic malignancies, including non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, myeloproliferative disorders, and myelodysplastic syndromes.
  2. Disorders of thrombosis and hemostasis, particularly in the cancer population.


Dr. Millensonson on My NCBI

  1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6. PubMed PMID: 25482239; PubMed Central PMCID: PMC434800
  2. Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI.Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20. doi: 10.1111/bjh.12915. Epub 2014 Apr 25. PubMed PMID: 24761968.
  3.  Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 1;120(13):1993-9. doi: 10.1002/cncr.28676. Epub 2014 Apr 4. PubMed PMID: 24706502; PubMed Central PMCID: PMC4130379.
  4. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21. PubMed PMID: 24264230.
  5. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20. PubMed PMID: 24111533.
  6. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddiqi T, Smith JL, Yee GC, Zakarija A, McMillian N, Naganuma M; National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013 Nov;11(11):1402-29. PubMed PMID: 24225973.
  7. Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 2013 Oct;37(10):1213-5. doi: 10.1016/j.leukres.2013.07.038. Epub 2013 Aug 7. PubMed PMID: 23968916; PubMed Central PMCID: PMC3976217.
  8. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul;11(7):838-74. PubMed PMID: 23847220; PubMed Central PMCID: PMC4000017.
  9. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17. PubMed PMID: 22006274

  10. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1. PubMed PMID: 22383795.

  11. LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar 1;119(9):2093-9. doi: 10.1182/blood-2011-07-369629. Epub 2012 Jan 10. PubMed PMID: 22234679.
  12.  Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009 Dec 29;7 Suppl 9:S1-16. PubMed PMID: 20064286.
  13. LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 1;26(31):5107-12. doi: 10.1200/JCO.2008.16.4061. Epub 2008 Sep 2. PubMed PMID: 18768434; PubMed Central PMCID: PMC2652094.
  14.  Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res. 2006 Oct 1;12(19):5809-16. PubMed PMID: 17020988.
  15.  Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk Lymphoma. 2006 Sep;47(9):1902-7. PubMed PMID: 17065004.